Safety & Efficacy Study of Gemcitabine...With High Dose IV Vit. C (HDIVC)
Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.
  • Phase

    Phase 1
  • Study Type

  • Intervention/Treatment

    gemcitabine vitamin c ...
  • Study Participants

The combination of gemcitabine and HDIVC is safe and may favorably change the clinical course for an individual patient.
The combination of gemcitabine and HDIVC is synergistic in anti-tumor effect as seen in preclinical models, where HDIVC creates a pro-oxidative effect that adds to the anti-tumor effect of gemcitabine.
The combination of gemcitabine and HDIVC may improve Progression Free Survival (PFS).
The dosage schema of 1.2 g /kg bolus infusion followed by lower dose of 0.3 g / kg infusion may create sustained elevation in Vitamin C plasma levels for increased cytotoxic effect.
The addition of HDIVC & oral supplementation of Vitamin C to standard treatment with gemcitabine may improve quality of life for patients with comparison to prior to treatment start of this protocol.
CA 19-9 and inflammatory markers may show trends for patients in this trial.
Study Started
Jun 30
Primary Completion
Jun 30
Study Completion
Jun 30
Results Posted
Dec 01
Last Update
Jul 26

Drug Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)

Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.

HDIVC Experimental

Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).


Inclusion Criteria:

Patient ≥ 18 years of age
Biopsy proven adenocarcinoma of the pancreas
Evidence of metastatic disease
Received at least 1 prior chemotherapy treatment regimen with disease progression
May have had any prior chemotherapy regimen including any gemcitabine based regimen or FOLFIRINOX
May have participated in a prior study protocol
May have had prior treatment with HDIVC
Anticipated survival of at least 3 months
Eastern Cooperative Oncology Group (ECOG) performance status = 0,1, or 2
The patient must have screening laboratory: ANC ≥ 1,500/mm3, Hemoglobin > 8g/dL, Platelets ≥ 100,000/mm3, Total Bilirubin < 1.5mg/dL, Creatinine ≤ 1.5mg/dL, Transaminases < 2.5 x upper limit of normal, Urine Uric Acid < 1.000 mg/d, Urine pH < 6, Urine microscopic negative for oxalates (if positive, reflex urinary oxalates < 60mg/d), PT INR ≤ 1.5, unless patient is on full dose warfarin
Glucose-6-phosphate dehydrogenase deficiency (G6PD) normal status via blood test The fluorescent spot test is the simplest, most reliable, and most sensitive of the G6PD screening tests
Willingness to undergo central line placement and able to manage care of the entry site safely
Willingness to adhere to supplemental oral dose regimen of ascorbic acid 500mg taken twice daily
All other nutritional supplements would be discontinued for the duration of the trial except for pancreatic enzymes and probiotics
Patients must be able to take food orally or have a peg tube for feeding
Able to give consent for protocol participation

Exclusion Criteria:

Glucose-6-phosphate dehydrogenase deficiency (G6PD)
Renal insufficiency : serum creatinine of > 1.5 mg /dl or evidence of oxalosis by urinalysis prior to enrollment and prior to each HDIVC infusion
Documentation or report of history of kidney stones or urinary oxalosis.
Co-morbid condition that would affect survival: congestive heart failure, unstable angina, myocardial infarction within 6 weeks of study, uncontrolled blood sugars of > 300 mg / dl, patients with known chronic active hepatitis or cirrhosis
Currently active second malignancy
Chronic hemodialysis
Iron overload/ Hemochromatosis: Ferritin > 500 ng / ml
Wilson's disease
Pregnant or lactating female (pre- menopausal females will undergo pregnancy test prior to administration of protocol drugs throughout treatment cycles during this study)
Aspirin use exceeding 81 mg per day
Acetaminophen use exceeding 2 g per day
Known brain metastasis
Active tobacco smokers
Treatment with the combination of HDIVC and gemcitabine previously



All Events

Event Type Organ System Event Term

Adverse Events as a Measure of Safety and Tolerability

Adverse events, whether volunteered by the study subject, discovered by the investigators during questioning, or detected by physical examination, laboratory tests, or other means will be collected and recorded at each visit. Events will be recorded from the time the consent is signed until 4 weeks after the study protocol is discontinued. Subjects experiencing Grade 4 neutropenia, Grade ≥3 thrombocytopenia, or Grade 2 peripheral neuropathy who do not recover will have treatment protocol discontinued.


Anti-Tumor Response

CT and PET scans will be performed at baseline and then every two months. Target and Non-Target Lesions will be identified and recorded at baseline. When subsequent scans are performed, anti-tumor responses will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST).


Age, Continuous

years (Mean)
Full Range: 52.0 to 59.0

Region of Enrollment

Sex: Female, Male

Overall Study